Lexeo Therapeutics’ gene therapy provides a healthy version of the frataxin gene, which is critical for energy production in ...

Lexeo Therapeutics announces positive interim phase 1/2 data for LX2006 in Friedreich ataxia cardiomyopathy: New York Wednesday, April 9, 2025, 12:00 Hrs [IST] Lexeo Therapeutics, ...

Stifel analysts said that Lexeo’s data showing reduced size and thickness of the heart’s left ventricle are “supportive of a drug effect” for the company’s gene therapy in Friedreich’s ataxia ...

The firm plans to use improvement in left ventricular mass index and increased frataxin protein expression after LX2006 treatment as co-primary endpoints.

Lexeo Therapeutics has posted updated data in Friedreich ataxia (FA) patients, linking a gene therapy to improvements on ...

Friedreich’s ataxia (FA) is a neurodegenerative disease most people have never heard of, and it remains widely misunderstood —and for the hundreds of Canadians who live with it, the lack of ...

Lexeo Therapeutics, Inc. ( ($LXEO) ) has shared an announcement. On April 7, 2025, Lexeo Therapeutics announced positive interim results from ...

Lexeo Therapeutics (LXEO) announced positive interim data across all dose cohorts of LX2006 for the treatment of Friedreich ataxia ...

"Late onset FA is a strange mix of feeling sad about the diagnosis and worrying about the future, and feeling happy that I ...

A West Annapolis family has turned two life-altering diagnoses into more than $1 million for research toward finding a cure ...

Larimar stock is down over 50% this year due to anaphylactic reactions in a study, rising expenses, and cautious market ...

Antibiotic drugs, which treat bacterial infections, are the primary form of treatment for bacterial pneumonia. Treatment is started as soon as possible, typically with oral antibiotics taken by mouth.